Ann Clin Med Res | Volume 2, Issue 1 | Short Communication | Open Access
Vidyadhar B Bangal
Department of Obstetrics and Gynecology, Rural Medical College, Maharashtra, India
*Correspondance to: Vidyadhar B Bangal
Fulltext PDFBackground: Labetalol is an anti-hypertensive agent with alpha adrenergic and non-selective betaadrenergic receptor blocking actions. It is recognized as first choice of antihypertensive agent in pre-eclampsia. Material and Methods: A prospective longitudinal study of 200 cases of moderate to severe pregnancy induced hypertension treated with Labetalol was conducted over a period of two years to find out maternal and perinatal outcome. Results: Labetalol therapy was effective in sixty four percent cases and pregnancy was continued for average of 16 days. Forty eight percent cases were delivered by caesarean section. One hundred and sixty four (82%) babies were live born. Four babies had intrauterine death (2%), thirty-two (16%) babies had fresh stillbirths and fourteen babies had early neonatal deaths. Conclusion: The effective control of blood pressure with the use of Labetalol was observed in sixty four percent cases of moderate to severe pregnancy induced hypertension.
Labetalol; Pre-eclampsia; Placental insufficiency
Bangal VB. Effect of Labetalol as an Antihypertensive Agent in PreEclampsia. Ann Clin Med Res. 2021; 2(1): 1020..